Nat Rev Endocrinol March 2014 PMID 24393785

Metformin--mode of action and clinical implications for diabetes and cancer.

Ida Pernicova, Márta Korbonits

Download social card

Mentions

16
Peak: 3 in Jun 2025
across 5 sources since Feb 2024

Extended reach

161,587
potential audience

Total likes

10,246

Video views

161,471

Mentions per month

Feb 2024 – Sep 2025

Where it's discussed

  • YouTube5 videos
  • Facebook4 posts
  • News3 articles
  • Blogs3 articles
  • X / Twitter1 posts

AI synopsis

What people are saying

The discussions show substantial engagement with the article’s content, citing specific studies like PRECAME, which explores metformin's cardiovascular effects in obese patients, and using terms like 'preventing' and 'potential' to highlight clinical significance; the tone suggests respect and curiosity about the implications for healthcare and future research.

AgreementModerate agreement

Most discussions align with the article's emphasis on metformin's diverse mechanisms and potential benefits.

InterestHigh interest

The discussions reveal high interest, especially with comments highlighting new research and clinical implications.

EngagementModerate engagement

Posts reflect moderate engagement, referencing specific studies like PRECAME and contemplating broader impacts.

ImpactModerate impact

Participants perceive the publication as impactful, particularly regarding its potential to influence treatment strategies and future research.

Abstract in brief

  • Metformin primarily lowers blood sugar by inhibiting liver gluconeogenesis, mainly by blocking mitochondrial complex I, which disrupts glucagon signaling.
  • Although activating AMP-activated protein kinase (AMPK) is not essential for its glucose-lowering effects, AMPK activation helps improve insulin sensitivity by affecting lipid metabolism.
  • Metformin may also impact cancer risk and development by reducing systemic insulin levels and inducing energetic stress within cells, but more research is needed to fully understand these effects.

Top posts

Most liked on X and Bluesky
Corpori Sano Biotechnology
@corporisanoclin · X

https://t.co/8yLZ9p9e3S. PRECAME Study: Preventing cardiovascular effects with metformin in obese patients ( Corpori Sano Biotechnology, Brasil

Feb 17, 2024 · 118 followers View post →

All mentions

Corpori Sano Biotechnology
@corporisanoclin · X

https://t.co/8yLZ9p9e3S. PRECAME Study: Preventing cardiovascular effects with metformin in obese patients ( Corpori Sano Biotechnology, Brasil

Feb 17, 2024 · 118 followers View post →